Healthy
Conditions
Brief summary
The purpose of this study is to evaluate the skin tolerance, instrumental efficacy, and perceived product efficacy of a whole-body balm on newborns (0-28 days old).
Interventions
OTHERWhole-body Balm
Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
OTHERWash and Shampoo
Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method.
Sponsors
Johnson & Johnson Consumer Inc. (J&JCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Days to 3 Months
Healthy volunteers
Yes
Inclusion criteria
Newborn participants only: * Male or Female * 0 to 3 months old, targeting at least 15 subjects in the 0 - 28 days age range at time of enrollment. * Has Parent Participant-reported Natural Skin tone/skin Color As Follows, including: (a) Skin tones Pale/fair to light white and/or White to light beige approximately 10 participants; (b) Skin tones Beige to light tan/light olive and/or Medium tan/medium olive to light brown approximately 10 participants; (c) Skin tones Medium brown to dark brown and/or Darkest brown to darkest black approximately 10 participants * Full term (37 plus weeks of gestation, both vaginal and Caesarean mode of delivery can be included) newborn Newborn participant and parent participant: * Generally, in good health based on medical history reported by the parent participant Parent participant only: * Able to read, write, speak, and understand English * At least 18 years old and is the parent (adoptive or biological), legal guardian, and primary caregiver of the newborn participant * Has signed the informed consent document (ICD) including Health Insurance Portability and Accountability Act (HIPAA) disclosure * Intends to complete the study and is willing and able to follow all study instructions
Exclusion criteria
Newborn participant only: * Presents with a skin condition that may influence the outcome of the study or increase risk to the newborn participant (example , psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer) * Has a family history of (defined as having a biological parent or full sibling with) eczema/atopic dermatitis * Has been bathed within 3 hours prior to Visit 1 * Has a clinical grade greater than 0 for rash/irritation, or greater than or equal to 1 for any of the other clinically assessed tolerance parameters at Visit 1 Newborn participant and parent participant: * Has known allergies or adverse reactions to common topical skincare products * Has self-reported (for the parent participant) or parent participant reported (for the newborn participant) Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication * Is taking a medication that would mask an AE or confound the study results, including (a) Immunosuppressive or steroidal drugs within 3 months before Visit 1; (b) Non-steroidal anti-inflammatory drugs within 5 days before Visit 1; (C) Antihistamines within 2 weeks (14 days) before Visit 1
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline After 4 Weeks of Product Use in Clinical and Parental Evaluations of Skin tolerance Measures | Change from baseline after 4 weeks | Change from baseline after 4 weeks of product use in clinical and parental evaluations of skin tolerance measures will be reported. The clinical and parental evaluations of tolerance will be recorded on paper source documentation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline After 7 Days of Product Use in Clinical and Parental Evaluations of Skin Tolerance Measures | Change from baseline after 7 days | Change from baseline after 7 days of product use in clinical and parental evaluations of skin tolerance measures will be reported. The clinical and parental evaluations of tolerance will be recorded on paper source documentation. |
| Change From Baseline After 7 Days of Product Use in Corneometer and Transepidermal Water Loss (TEWL) Measurements | Change from baseline after 7 days | Change from baseline after 7 days of product use in Corneometer and TEWL measurements will be reported. The Corneometer measures moisture content in the stratum corneum by an electrical capacitance method. Readings are proportional to the dielectric constant of the surface layers of the skin, and the results are displayed in arbitrary Corneometer units ranging from 0 to 120, with increasing values corresponding to more hydrated skin. TEWL is a equipment with open chamber TEWL probes to measure the TEWL of the skin. The non-invasive probe contains two sensors that measure the temperature and relative humidity at two fixed points along the axis normal to the skin surface. |
| Change From Baseline After 4 Weeks of Product Use in Corneometer and Transepidermal Water Loss (TEWL) Measurements | Change from baseline after 4 weeks | Change from baseline after 4 weeks of product use in Corneometer and TEWL measurements will be reported. The Corneometer measures moisture content in the stratum corneum by an electrical capacitance method. Readings are proportional to the dielectric constant of the surface layers of the skin, and the results are displayed in arbitrary Corneometer units ranging from 0 to 120, with increasing values corresponding to more hydrated skin. TEWL is a equipment with open chamber TEWL probes to measure the TEWL of the skin. The non-invasive probe contains two sensors that measure the temperature and relative humidity at two fixed points along the axis normal to the skin surface. |
| Number of Response Options for Each Question in the Parental Questionnaire | Day 28 | Number of response options for each question in the parental questionnaire will be reported. Parental questionnaire will be completed by the parent participants which include the questions about how much do you agree after using balm where 1 indicates 'strongly disagree', 2 indicates 'somewhat disagree', 3 indicates ;neither agree or disagree', 4 indicates 'somewhat agree', 5 indicates 'strongly agree'. |
| Percentage of All Response Options for Each Question in the Parental Questionnaire | Day 28 | Percentage of all response options for each question in the parental questionnaire will be reported. parental questionnaire will be completed by the parent participants which include the questions about how much do you agree after using balm where 1 indicates 'strongly disagree', 2 indicates 'somewhat disagree', 3 indicates ;neither agree or disagree', 4 indicates 'somewhat agree', 5 indicates 'strongly agree'. |
Countries
United States
Outcome results
None listed